Senses Disorder TRIZ Cases

Chemical modifications to antisense oligonucleotides increase SIRT1 mRNA levels by enhancing binding specificity and nuclease stability.

Quinone-modified nitric oxide donors reduce intraocular pressure while minimizing nitrate tolerance and providing antioxidant protection.

Specific chemical structures enhance CFTR protein trafficking and ion transport to address defective protein handling in cystic fibrosis.

Sequential marker selection eliminates neuronal and astrocytic contaminants to yield high-purity oligodendrocyte-biased glial progenitor cells.

Peptides selectively inhibit p53-mediated cell death to reduce normal tissue damage during cancer therapy.

Benzylideneguanidine derivatives inhibit the PPP1R15A phosphatase to restore cellular protein homeostasis without triggering blood pressure decreases.

Short synthetic peptides induce survivin expression to treat retinal degenerative diseases while promoting tissue repair.

Amide compounds suppress viral replication to treat RNA and DNA viruses without toxicity.

Triblock copolymer coating reduces mucoadhesiveness to enable mucus penetration, resolving the trade-off between drug retention and tissue access.

Compounds inhibit SARM1 NADase activity to maintain axonal NAD+ levels and prevent neurodegeneration in Parkinson's disease.

Pyrazine compounds with localized substituent patterns selectively inhibit Syk kinase, avoiding off-target effects on other kinases.

A cyclic amine derivative inhibits RORγ activity to treat autoimmune and allergic diseases.

Fusing FLT-1 or KDR extracellular domains with the human IgG1 Fc region extends serum half-life and enhances anti-tumor efficacy against angiogenesis.

1,4-diaryl-pyrimido[4,5-d]pyridazine-2,5-dione derivatives inhibit human neutrophil elastase with high selectivity and stability.

Spiro derivatives modulate CRTH2 activity to treat allergic diseases, addressing limited efficacy and side effects of existing therapies.

CRISPR-Cas9 excises the USH2A c.2299delG mutation, halting visual loss progression in Usher Syndrome Type 2a.

Specific X-ray powder diffraction patterns stabilize the crystalline form, resolving manufacturing complexity while enhancing CFTR modulation effectiveness.

NRP1 inhibitors block semaphorin signaling to reduce inflammatory responses in septic shock and cerebral ischemia.

Selective alpha-2B agonists resolve T cell modulation limits by increasing regulatory T cells and reducing immune infiltration.

Amino acid substitutions in variant AAV capsids boost retinal cell transduction efficiency while maintaining structural stability.

Topical cannabinoid compositions reduce inflammation and address bacterial causes to prevent corneal ulceration.

(+)-Morphinan compounds inhibit Toll-like receptor 9 activation, blocking glial cell activation and reducing pro-inflammatory factor release.

Antibodies bind selectively to the transglutaminase type 2 core region, eliminating off-target effects from non-selective inhibitors.

Chemical coupling of ligands to AAV capsid amino groups via thiourea bonds overcomes broad biodistribution and toxicity issues.

Hyaluronic acid stimulates junctional complex restoration to enhance mucosal protective integrity.

Modifying 5,6-dihydroimidazo[1,5-a]pyrazinyl derivatives improves BACE inhibition potency while maintaining a safe cardiovascular profile.

Crude Dunaliella powder with specific beta-carotene isomer ratios targets cone and rod photoreceptor cells to enhance visual function.

Caspase inhibitors treat Fuchs' dystrophy by suppressing TGF-beta signals to maintain cell density and corneal transparency without donor tissue.

Formula I amidoxime prodrugs selectively inhibit sphingosine kinase isoforms, resolving metabolic stability and bioavailability trade-offs.

MANF and CDNF peptides preserve sensory cells against ototoxicity and retinal degeneration via versatile administration.

Wood creosote inhibits acetylcholinesterase to treat dementia while avoiding the vomiting and diarrhea caused by conventional synthetic inhibitors.

A cyclic olefin resin container increases the dynamic contact angle of an ophthalmic composition to suppress surface wetting.

Targeted amino acid substitutions in mutated channelrhodopsin proteins boost photosensitivity, restoring visual function at low light intensities.

Polyvinyl pyrrolidone shields brivudine from photodegradation, maintaining antiviral efficacy for herpetic keratitis treatment.

Selective HCN channel blockade improves retinal ganglion cell function while minimizing off-target side effects.

Exosome-delivered recombinant cystinosin reduces lysosomal cystine without the odor and compliance issues of cysteamine bitartrate.

Formula I and I' compounds selectively target PAD4 over PAD2 to reduce citrullination levels in rheumatoid arthritis treatment.

Substituted pyrimidine compounds inhibit phosphatidylinositol 3-kinase delta to resolve insufficient potency in current selective inhibitors.

Isolating native HC-HA/PTX3 complexes from fetal tissues enables scalable in vitro reconstitution to modulate inflammatory responses.

Substituted heteroaryl compounds selectively inhibit Syk kinase, reducing off-target effects on Aurora B and FLT-3.

Irreversible Btk inhibitors form a covalent bond with the cysteine residue on Bruton's tyrosine kinase to achieve sustained enzyme inhibition.

Polyvalent nanoconjugates traverse the blood-brain barrier using transferrin conjugation for targeted central nervous system delivery.

Sustained release compstatin analogs inhibit local complement activation in the respiratory tract, avoiding systemic side effects from chronic dosing.

2-Phenyl-indole compounds block the prostaglandin D2 receptor, resolving inadequate symptom management in allergic rhinitis and asthma.

Short interfering RNAs inhibit p53 gene expression, reducing adverse side effects from cancer treatments while protecting normal cells.

rAAV9 vectors deliver TPP1 genes to retinal cells, halting vision loss progression without frequent biweekly infusions.

Segmented antibody variants target distinct amyloid conformations to reduce plaque burden, addressing the lack of effective therapies for Alzheimer's disease.

Selective p38 gamma and delta inhibitors reduce systemic toxicity while extending lung residency times for chronic inflammatory disease treatment.

Chromane and quinone derivatives target mitochondrial iron overload, reducing oxidative stress to slow Friedreich's ataxia progression.